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Abstract 
Measuring changes in tumor volume using anatomical imaging weeks to months post radiation 
therapy (RT) is currently the clinical standard for indicating treatment response to RT. For patients 
whose tumors do not respond successfully to treatment, this approach is suboptimal as timely 
modification of the treatment approach may lead to better clinical outcomes. We propose to use 
tumor microvasculature as a biomarker for early assessment of tumor response to RT. Acoustic 
angiography is a novel contrast ultrasound imaging technique that enables high-resolution 
microvascular imaging and has been shown to detect changes in microvascular structure due to 
cancer growth. Data suggest that acoustic angiography can detect longitudinal changes in the 
tumor microvascular environment that correlate with RT response.  
Methods: Three cohorts of Fisher 344 rats were implanted with rat fibrosarcoma tumors and 
were treated with a single fraction of RT at three dose levels (15 Gy, 20 Gy, and 25 Gy) at a dose 
rate of 300 MU/min. A simple treatment condition was chosen for testing the feasibility of our 
imaging technique. All tumors were longitudinally imaged immediately prior to and after treatment 
and then every 3 days after treatment for a total of 30 days. Both acoustic angiography (using 
in-house produced microbubble contrast agents) and standard b-mode imaging was performed at 
each imaging time point using a pre-clinical Vevo770 scanner and a custom modified dual-frequency 
transducer.  
Results: Results show that all treated tumors in each dose group initially responded to treatment 
between days 3-15 as indicated by decreased tumor growth accompanied with decreased vascular 
density. Untreated tumors continued to increase in both volume and vascular density until they 
reached the maximum allowable size of 2 cm in diameter. Tumors that displayed complete control 
(no tumor recurrence) continued to decrease in size and vascular density, while tumors that 
progressed after the initial response presented an increase in tumor volume and volumetric 
vascular density. The increase in tumor volumetric vascular density in recurring tumors can be 
detected 10.25 ± 1.5 days, 6 ± 0 days, and 4 ± 1.4 days earlier than the measurable increase in 
tumor volume in the 15, 20, and 25 Gy dose groups, respectively. A dose-dependent growth rate 
for tumor recurrence was also observed.  
Conclusions: In this feasibility study we have demonstrated the ability of acoustic angiography to 
detect longitudinal changes in vascular density, which was shown to be a potential biomarker for 
tumor response to RT. 










Radiation therapy (RT) is one of the most 
common cancer treatment modalities and is used to 
treat 30-70% of all cancer patients in North America 
alone, by itself or in combination with surgery or 
chemotherapy [1]. RT is used either with curative 
intent for complete tumor eradication or local control, 
or with palliative intent to reduce tumor growth and 
symptom control. Unfortunately, patients often have 
varied tumor responses to RT due to differences in 
tumor type and other genetic and epigenetic factors 
[2]. Furthermore, the biological mechanisms of RT 
effects are still not well understood enough for 
clinicians to account for this variability [3]. For many 
types of cancers, the current clinical standard for 
assessing response to RT is RECIST (Response 
Evaluation Criteria in Solid Tumors), in which 
changes in tumor size are measured with MR and CT 
diagnostic imaging [4]. Unfortunately for patients 
receiving RT, the extent of tumor control (complete 
reduction in tumor size, tumor shrinkage, or cessation 
of tumor progression) is often not measurable until 
months after treatment [5]. Since a timely switch to an 
alternative treatment approach may lead to a better 
prognosis in cases where RT is not effective, it is 
important to determine response to therapy as early 
as possible [6]. The ability to measure early 
physiological biomarkers that indicate treatment 
failure prior to long term changes in tumor size would 
represent a significant advancement in early 
treatment response detection.  
 Hanahan et al proposed six “hallmarks of 
cancer” consisting of molecular characteristics of the 
tumor microenvironment that contribute to the 
development and proliferation of tumors, one of 
which is aberrant angiogenesis. Tumor 
neovascularization is signified by excessive sprouting 
of tortuous vessels within or near the tumor area, 
therefore increasing vessel density and in some cases, 
perfusion [7]. The tumor microvascular environment 
also plays an important role in the efficacy of RT. 
Endothelial apoptosis of tumor microvasculature is 
known to be a homeostatic factor in the regulation of 
tumor growth and is strongly correlated with tumor 
control when treated with radiation, therefore 
suggesting that DNA damage and consequential cell 
death due to exposure to ionizing radiation may not 
be the only significant factor determining the effect of 
RT [8]. Additionally, microvascular remodeling and 
angiogenesis after RT has been observed in animal 
models within two days of treatment using intravital 
optical microscopy, which demonstrates the highly 
dynamic nature of the tumor microvasculature [9]. 
While the biological basis of vascular remodeling is 
not entirely understood, patterns in the microvascular 
response to treatment may be a tell-tale sign of the fate 
of the treated tumor that can be discerned remarkably 
soon after therapy. Currently, there are very few 
clinical technologies available that have the sensitivity 
to measure microvascular structure. In this study, we 
propose a contrast ultrasound imaging technique to 
image and characterize tumor microvasculature in 
terms of volumetric vascular growth. We hypothesize 
that changes in tumor microvasculature caused by RT 
occur sooner than changes in tumor volume, and 
therefore can potentially be used as a biomarker for 
predicting tumor control. 
Contrast enhanced ultrasound (CEUS) is a 
low-cost , non-ionizing, and safe imaging modality 
that can visualize and measure vascularity and 
perfusion in tissue with high contrast sensitivity 
compared to CT and MR [10]. The microbubble 
contrast agents used for CEUS are composed of a gas 
core and a stabilizing shell. Typically, the core consists 
of an inert gas such as a perfluorocarbon or sulfur 
hexafluoride, and common shell materials include 
PEGylated phospholipids or albumin. The gas is 
exhaled out through the lungs and the shell 
components are filtered and excreted through the 
liver and spleen via the reticuloendothelial system 
and phagocytic mechanisms [11]. Microbubbles are 
non-toxic unlike MR and CT gadolinium based and 
iodinated contrast agents, which are contraindicated 
in various patient populations due to their 
nephrotoxicity [12]. Commercial microbubbles are 
polydisperse and typically range from 1-5 µm in 
diameter, constraining them within the vasculature 
[13].  
Advanced CEUS techniques can yield 
quantitative diagnostic information, including 
relative tissue enhancement, tissue perfusion, 
expression of endothelial biomarkers, and vascular 
structure [14–17]. CEUS perfusion imaging and 
molecular imaging (used for measuring tissue 
perfusion and endothelial molecular expression, 
respectively) have been investigated extensively in 
both pre-clinical and clinical settings for measuring 
vascular response to therapy and both short and 
long-term effects on tumor control [16,18,19]. 
Angiogenic-based cancer therapeutics (i.e. sunitinib, 
bevacizumab, sorafenib, Dll4-notch inhibitors) and RT 
alter the expression of angiogenic factors, thus 
interfering with microvascular growth or inflicting 
injury to the endothelium resulting in severe local 
hypoxia and tumor growth delay [20–23]. Molecular 
imaging has been shown to detect changes in 
angiogenic and inflammation endothelial biomarkers, 
such as vascular endothelial growth factor and 
P-selectin, that may predict response to therapy 
[16,24,25]. Perfusion imaging techniques, such as 





power Doppler and destruction reperfusion, have also 
demonstrated that tumor blood flow changes caused 
by RT by itself or in combination with adjuvant 
chemotherapy can be detected within days after 
treatment [18,26–29].  
Acoustic angiography (AA) is a super-harmonic 
CEUS imaging technique that enables high-resolution 
microvascular imaging. This technique requires a 
confocal dual-frequency transducer design with a low 
frequency element to transmit and a high frequency 
element to receive at several harmonics higher than 
the transmit frequency [30]. The large bandwidth 
separation of the transmit and receive frequencies 
enables the detection of broadband microbubble 
signals while rejecting linear tissue signal. 
Reconstructing a stack of 2D images using this 
dual-frequency technique results in a high-resolution 
(100-200 µm) and high contrast-to-tissue ratio (30-40 
dB) 3D image volume of the underlying 
microvasculature (Figure 1).  
These images can be subsequently segmented 
and analyzed to quantify vascular features such as 
vascular density, vessel tortuosity, and vessel 
diameter and can also be used to better assess the 
tumor boundary since abnormal microvasculature 
extends beyond the physical tumor space. Vessel 
morphology and density cannot be directly quantified 
with other clinically existing CEUS technologies due 
to the resolution limitations and relatively low 
signal-to-noise ratio. We have previously shown that 
quantitative acoustic angiography can detect and 
quantify abnormal vascular density and vessel 
tortuosity in areas of cancer growth compared to 
healthy tissue [31,32]. Our objective in this study is to 
demonstrate the sensitivity of acoustic angiography to 
detect and quantify changes in tumor vascular density 
in response to RT as an indicator for long-term 
treatment success or failure. We propose to begin this 
investigation under a simple high-dose single fraction 
treatment condition to demonstrate feasibility and 
potential benefit of our technique.  
Materials and Methods 
Rat and Tumor Models 
All animal surgical and imaging procedures 
were reviewed and approved by the University of 
North Carolina at Chapel Hill Animal Care and Use 
Committee prior to conducting this study. Rat 
fibrosarcoma (FSA) tumor tissue gracious provided 
by the Dewhirst lab at Duke University was 
subcutaneously implanted in the right flank of 30 
female Fischer 344 rats as previously described [33]. 
The rat FSA model was originally induced and 
isolated from Fischer 344 rats injected with the 
carcinogen, methylcholanthrene [34]. Rat FSA is 
characterized as a local, non-metastasizing tumor that 
is highly vascular and oxygen dependent [34, 35]. 
Because of its high vascularity, it is an appropriate 
tumor model for acoustic angiography imaging after 
RT, since we are specifically interested in the tumor 
vascular response to therapy. Because rat FSA is 
oxygen dependent, avascular regions typically 
undergo tissue necrosis [35].  
 
 
Figure 1. A) B-mode image in the coronal view of a tumor located in the right flank of a rat indicated with yellow arrows. B) A coronal maximum intensity projection 
of 3D intensity data from a stack of 2D acoustic angiography images in the same imaging area. Using acoustic angiography we can visualize the tumor tissue and 
microvasculature with exceptional tissue rejection.  





Radiation Therapy and Monitoring 
Once the tumors reached their target treatment 
size of 5-10 mm in diameter in the longest dimension 
of the sagittal plane, the tumors were given a single 
dose of radiation. The rats were split into four 
different dose cohorts and received either 0 Gy 
(treatment control, n=9), 15 Gy (n=8), 20 Gy (n=5), or 
25 Gy (n=8) of radiation. The dose levels were 
determined during a longitudinal pilot RT study 
(unpublished) that was conducted at 0, 5, and 20 Gy. 
We found that 5 Gy had no tumor control, and 20 Gy 
had roughly 50% local control (tumor shrinkage and 
eventual disappearance) and 50% local failure (initial 
tumor shrinkage followed by a delayed tumor 
regrowth). We selected a dose level of 15-25 Gy as it 
allowed us to investigate the dose dependent 
correlation between TV change and VVD change for 
both local control and local failure groups with similar 
statistics. 
The rats were anesthetized using vaporized 
isoflurane and oriented in the left lateral recumbent 
position on a heating pad throughout the duration of 
the treatment with front and rear paws stabilized on 
the heating pad with medical tape. Positioning was 
performed using a rotatable rat positioning table 
(VisualSonics, Toronto Canada) so that the tumor was 
completely irradiated while minimizing exposure to 
the abdominal region (Figure 2). The rats were treated 
with a Primus II clinical linear accelerator (Siemens 
Healthcare, Malvern, PA) with a dose prescription of 
6 MV photons, 2 cm x 2 cm collimated radiation field 
size at 100 cm source-to-skin-distance (SSD), and 1 cm 
of water-equivalent build-up material. All rats were 
monitored daily for the first 2 weeks following 
treatment, and then every third day thereafter. 
Additionally, the animals were all fed identical diets 
consisting of regular protein pellets and both 
calorie-rich and hydrating gels to mitigate excessive 
weight-loss and water-loss due to dehydration in the 
case of intestinal distress caused by radiation enteritis. 
 
 
Figure 2. Setup used for irradiation and ultrasound imaging. A) (Front view) For irradiation, the rat was positioned on a heating pad mounted to a 3-axis rotatable 
base. The heating pad was rotated to an angle such that the irradiation beam was centered on the tumor while minimizing exposure to the abdominopelvic region. The 
1 cm water-equivalent bolus was then placed on top of the tumor region. B) (Top view) The rat was secured to the heating pad using medical tape. A 2 cm x 2 cm 
irradiation field size was used. C) (Front view) For imaging, the rat was positioned on the same heating pad, oriented parallel to the floor such that the tumor was 
facing up. A custom designed water bath was used to separate the transducer from the gel while still being continuously coupled to the tumor, so that the mechanical 
translation of the transducer would not displace the gel causing decoupling and introducing air bubbles. D) (Side view) The transducer was mechanically translated in 
the elevational dimension for 2 cm for each scan.  






Rats were imaged immediately prior to radiation 
for baseline measurements. After the radiation 
treatment, imaging was performed daily for 3 
consecutive days and then every 3 days for 
approximately 30 days or until the tumors reached the 
maximum size of 2 cm in the longest diameter.  
During each imaging session, the rats were 
anesthetized using vaporized isoflurane and 
positioned on a heating pad as described above. A tail 
vein IV catheter was inserted for constant 
microbubble contrast infusion during acoustic 
angiography imaging. Microbubble contrast agents 
were prepared in-house using sterile techniques, as 
previously described [33]. The contrast was diluted 
with 0.9% sterile saline in a 1:1 ratio. The contrast 
agent was administered as a small bolus of 50 µL 
immediately followed by a constant rate of infusion of 
40 µL/min using a pre-clinical infusion pump. 
Contrast was infused for 30 s before imaging was 
initiated to allow contrast flow to achieve a steady 
state and then was continued for the duration of the 
imaging scan. A total contrast volume of 
approximately 180 µL was injected for one acoustic 
angiography scan. The tumor region of the rat was 
shaved and depilated and ultrasound gel was applied 
onto the tumor region for ultrasound coupling. A 
custom imaging bath was used for all imaging to 
minimize gel decoupling during mechanical 
translation of the transducer (Figure 2). All imaging 
was performed on a Vevo 770 pre-clinical ultrasound 
scanner (VisualSonics, Toronto, ON, Canada) with a 
custom prototype dual-frequency transducer 
modified from a VisualSonics RMV707 probe, as 
previously described [36]. This transducer utilized a 4 
MHz transmitter and a 30 MHz receiver, and was 
mechanically swept to acquire 2D images, and then 
translated in the elevational axis to acquire 3D data. A 
b-mode (anatomical) image volume was acquired 
over a 2 cm region, followed by an acoustic 
angiography scan over the same region. The 
elevational step size for each image was 100 µm. 
Two-frame averaging with a frame rate of 3 frames/s 
was used for all acoustic angiography imaging to 
improve the signal-to-noise ratio for producing 
optimal images. 
Image Analysis 
The b-mode images were used to calculate tumor 
volume (TV). The caliper feature on the Vevo 770 
imaging software was used to measure the longest 
tumor diameter in each image axis to approximate the 
ellipsoidal volume of the tumor. The acoustic 
angiography images were post-processed using 
MATLAB (MathWorks, Natick, MA) to measure 
volumetric vascular density (VVD). It is important to 
identify and remove large hypoechoic regions to not 
overestimate the total perfused tissue volume [37,38]. 
We assumed that large hypoechoic regions were due 
to necrosis and hypoxia, based on tumor ex vivo 
observations and prior literature that describes rat 
FSA as a highly oxygen dependent tumor [35]. These 
hypoechoic regions will be referred to as “necrotic” 
for simplicity, which encompasses necrotic and 
perinecrotic regions. For identifying necrotic regions, 
a de-noising 2D median filter was applied to each 
frame of the acoustic angiography image slices to 
smooth the image and then a threshold was used to 
create a binary mask that identified large dark 
regions. This binary mask was then applied to the 
corresponding frame of the original acoustic 
angiography image followed by subsequent 
thresholding to identify the vessels using the local 
Otsu threshold method [39]. VVD was calculated by 
dividing the number of pixels representing vessels by 
the number of pixels representing the tumor tissue 
sans necrosis (Figure 3).  
 
 
Figure 3. Summary of the image analysis for calculating VVD. A single 2D slice 
of a 3D volume is shown in this figure. A) The original acoustic angiography 
region of interest (ROI). B) The original image, de-noised with a 2D median 
filter. C) The binary vessel image of the original ROI produced by applying an 
Otsu threshold. D) The hypoechoic mask made by applying a threshold on the 
de-noised image (B). E) The mask (D) applied to the binary vessel image (C). 




At the end of the study, treated rats were 
retrospectively categorized based on the treatment 





outcome as either local failure (initial treatment 
response followed by tumor recurrence) or local 
control (full treatment response resulting in complete 
tumor disappearance). The 20 Gy study was 
terminated early at day 20 due to imaging schedule 
constraints. All local control tumors were monitored 
for the duration of the study (30 days) for tumor 
regrowth, followed by an additional 30 days.  
TV and VVD growth curves for all individual 
rats were normalized by their respective baseline 
(pre-treatment) values. Initial TV growth curves 
(before tumor regression) and tumor recurrence rates 
were characterized by calculating their doubling 
times (Dt) using the following equation, where Dt is 
the doubling time, T0 is the time of initial 
measurement, V0 is the initial volume, and Vf is the 
final volume: Dt = (T – T0) × (log(2)/log(Vf)) – log(V0). 
Similarly, TV regression was characterized by 
calculating the tumor halving times (Ht) using the 
following equation: Ht = (T – T0) × (log(1/2)/log(Vf)) – 
log(V0) [40]. 
Different phases of the VVD curves (initial 
response, regression, and recurrence phases) were 
characterized using linear regression.  
TVx and VVDx represent the beginning of the 
recurrence phase for tumor volume and volumetric 
vascular density measurements, respectively, for an 
individual tumor. Statistical differences in growth 
curves and TVx and VVDx values were evaluated 
using the Mann-Whitney U-test, and differences 
observed between dose groups were evaluated with 
the Kruskal-Wallis test, followed by the Tukey 
Post-Hoc multiple comparison test (α = 0.05). All 
statistical analysis was performed in MATLAB. 
Results 
The treatment response statistics and sample 
sizes for each dose group are summarized in Table 1. 
Local failure, local control and untreated tumors in 
each dose group present distinctly different VVD and 
TV growth curves (Figure 4).  
 
Table 1. Treatment Response Statistics by Dose Group 
Summary statistics of the treatment outcomes for each dose 
group. Local tumor failure refers to tumors that initially responded 
but regrew and progressed, and local tumor control refers to 
tumors that completely disappeared after treatment. 
 15 Gy 20 Gy 25 Gy 
Local Tumor Failure 5 (63%) 3 (60%) 3 (38%) 
Local Tumor Control 3 (38%) 2 (40%) 5 (63%) 
Total Treated Tumors: 8 5 8 
 
Initial Response 
Untreated tumors underwent normal, 
uninterrupted exponential volume growth with a 
mean doubling time of 1.9 ± 0.5 days (median: 1.9 
days; range: 1.4 days; IQR: 0.6 days). All treated 
tumors presented delayed tumor volume growth after 
the treatment (day 0) until day 3, at a growth rate 
significantly less (p=0.009) than the untreated tumors 
with a mean tumor doubling time of 3.8 ± 2.6 days 
(median: 3.2 days; range: 11.7 days; IQR: 2.0 days). 
There was a non-significant decrease in the average 
tumor doubling time for treated tumors as RT dose 
increased. VVD of all treated tumors increased by an 
average of 18 ± 13%, significantly greater (p=0.023) 
than in untreated tumors, which increased by 4 ± 6%. 
There were no significant VVD or TV differences 
between local failure and local control tumors within 
each dose group (Table 2). 
 
Table 2. Tumor Volume and Volumetric Vascular Density Growth Curve Statistics Statistical analysis of tumor volume and 
volumetric vascular density growth curves for each dose group. Significant differences were observed in TV doubling time and VDD 
increase, immediately post-treatment. Treated tumors experienced delayed tumor growth (increased TV doubling time) immediately 
after treatment while VVD in treated tumors increased at a significantly higher rate than untreated tumors. There were no other 
statistically significant growth curve trends between treated and untreated, and local control and local failure tumors. 
 Untreated All Treated 15 Gy 20 Gy 25 Gy 
Local Control Local Failure Local Control Local Failure Local Control Local Failure 
Tumor Volume Doubling time – 
Initial Response (days) 
1.9 ± 0.5 3.8 ± 2.6 
(p=0.009) 
5.6 ± 3.4 3.4 ± 0.5 2.4 ± 1.4 
5.5 ± 1.2 5.7 ± 4.7 3.6 ± 0.7 3.3 ± 0.3 2.3 ± 1.3 2.4 ± 1.9 
Volumetric Vascular Density 
increase – Initial Response (%) 
4.3 ± 6.1 18.1 ± 12.7 
(p=0.023) 
21.0 ± 15.8 26.5 ± 10.2 10.0 ± 5.1 
22.3 ± 21.3 20.5 ± 14.0 23.8 ± 15.3 28.3 ± 8.9 8.6 ± 5.9 12.4 ± 2.9 
Tumor Volume Halving time – 
Regression (days) 
~ 3.0 ± 1.0 3.2 ± 0.7 2.8 ± 0.3 2.9 ± 1.4 
2.5 ± 0.3 3.8 ± 0.5 3.0 ± 0.6 2.7 ± 0.1 2.1 ± 0.3 1.3 ± 1.6 
Volumetric Vascular Density 
Regression (%) 
~ -12.8 ± 9.3 -10.9 ± 4.9 -20.9 ± 14.7 -9.3 ± 5.0 
-10.4 ± 6.1 -11.7 ± 3.5 -26.0 ± 19.6 -17.5 ± 14.1 -11.1 ± 5.7 -6.2 ± 1.0 
Tumor Volume Doubling time – 
Recurrence (days) 
~ 4.7 ± 2.1 3.6 ± 0.8 6.4 ± 3.4 4.5 ± 1.2 
Volumetric Vascular Density 
recurrence (%) 
~ 5.2 ± 3.2 7.2 ± 3.6 4.7 ± 3.3 3.2 ± 1.4 






Figure 4. A comparison of tumor volume (A, C, E) and tumor microvascular density (B, D, F) growth curves for local control (solid black), local failure (dotted black), 
and untreated tumors (solid gray) for each dose group. Sample sizes for local control, local failure, and untreated groups were 3, 4, and 2 for the 15 Gy group, 2, 3, 
and 5 for the 20 Gy group, and 5, 3, and 2 for the 25 Gy cohorts, respectively. Error bars represent standard deviation. Local failure tumors undergo a transient 
decrease in vascular density that correlates with tumor regression and eventually increases, correlating with tumor recurrence. For local control tumors, both TV and 
VVD decrease. The large error bars in TV and VVD curves are expected due to variability in tumor growth as well as heterogeneity of vascular supply.  
 
Tumor Regression 
By day 5, all treated tumors experienced tumor 
regression where both tumor volume and vascular 
density decreased. There was no statistical difference 
in the regression rates of either TV or VVD between 
local control and local failure tumors in the 15, 20, and 
25 Gy treatment groups. For local control tumors, the 
tumors continued to shrink and completely 
disappeared between days 15 and 20, accompanied 
with decreasing VVD (Table 2).  
Tumor Recurrence 
All local failure tumors rebounded and recurred 
between days 10 and 20 as indicated by their TV 
growth curves. VVD began to increase between days 7 





and 11 and was also associated with tumor 
recurrence. Tumor recurrence occurred 
(non-significantly) earlier as dose increased as 
indicated by decreasing average TVx; VVD recurrence 
(average VVDx) was not statistically different between 
dose groups. When comparing TV and VVD curves 
for each individual tumor, the increase in VVD was 
observed earlier than the increase in TV (Figure 5). 
Figure 6 visually illustrates TV and VVD changes 




Figure 5. Example of vascular density (left) and tumor volume (right) growth curves from a 15 Gy local failure. All measurements were normalized to baseline values. 
In this particular local failure, vascular density begins to increase as early as day 8, while tumor volume regrowth occurs later. The increase in the growth curve for 
both metrics demarcates the recurrence phase for local failure tumors, which is illustrated by the shaded region. The tumor volume and vascular density growth 
curves of local failure tumors in each dose group behaved similarly. 
 
 
Figure 6. A visual comparison of vascular density and tumor volume changes during the tumor regrowth phase of the same 15 Gy local failure tumor plotted in Figure 
4. Vascular density (right) noticeably increases from day 7 to day 19, while tumor volume (left) size continues to decrease until day 19. The tumor boundary in the 
b-mode images is indicated by the solid yellow line. Note that microvascular data is shown as a maximum intensity projection but is actually a 3-D data set. 





Increase in VVD for individual rats was 
observed 10.25 ± 1.5 days, 6 ± 0 days, and 4 ± 1.4 days 
earlier than increases in TV, in the 15 Gy*, 20 Gy*, and 
25 Gy cohorts, respectively (Figure 7, *p<0.05). The 
initial tumor volumes were 157.8 ± 5.9 mm3, 182.9 ± 
68.1 mm3, 201.4 ± 77.4 mm3, for the 15, 20, and 25 G 
groups, respectively. Variation in initial tumor 
volumes between groups was due to tumor growth 
difficulties; specifically, at the time of treatment, 
tumors either did not develop or grew too large (>1 
cm in diameter) to be continued in the study. There 
were non-statistically significant differences in TV 
and VVD measurements between local controls and 
local failures; specifically, local failures exhibited 
higher TVs and VVDs (Table 3).  
 
 
Figure 7. Dose dependence of the early detection of treatment failure by 
tumor vascular density. Local failure identification using vascular density (black) 
occurred earlier than using tumor volume (gray). With increasing dose, the 
difference in the time of identification between vascular density and tumor 
volume decreased. ([*] significant at p < 0.05).  
 
Table 3. Average Initial TV and VVD Values Average initial 
tumor volume and initial vascular density values for each dose 
group. Larger initial tumor volumes were associated with local 
failure. While not statistically significant, the average initial vascular 
density for local failure tumors was greater than local tumor 
control. This became less pronounced as dose increased. 
Dose 
(Gy) 
Average Initial TV (mm3) 
(*p<0.05) 
Average Initial VVD 
(*p<0.05) 
Local Failure Local Control Local Failure Local Control 
15 171 ± 52 108 ± 40 0.25 ± .04 0.16 ± 0.10 
20 230 ± 67 137 ± 110 0.26 ± 0.01 0.20 ± 0.05 
25 290 ± 77 169 ± 39* 0.27 ± 0.02 0.25 ± 0.04 
 
 
No severe adverse health effects or significant 
weight loss were observed in any of the rats during 
the entirety of the study. The orientation of the rat 
during treatment minimized irradiation of the 
abdominopelvic region, resulting in less toxicity than 
in our previous studies where the rat was oriented 
perpendicular to the radiation beam. Mild radiation 
enteritis was experienced by fewer than 5 rats, which 
resulted in loose stool and an average of 5 g or 3% loss 
of body weight. This was mitigated with 
supplementary high calorie food and hydrogel water 
(Methods section). All rats with recurring tumors 
were euthanized at the end of the study. Rats with 
successfully treated tumors have been kept 
indefinitely (>180 days) since the end of the study and 
have not shown any signs of tumor recurrence. 
Discussion 
We have previously demonstrated that acoustic 
angiography can visualize microvasculature with 
high-resolution, and various quantitative metrics are 
sensitive to certain abnormal microvascular structural 
properties (e.g. tortuosity, density) that allow us to 
discern cancerous tissue from normal tissue [31,32]. 
Based on previous research that has demonstrated 
that microvascular remodeling occurs within days 
after radiation exposure using optical imaging, we 
hypothesized that quantification of microvascular 
changes using acoustic angiography may indicate 
response to therapy sooner than using tumor volume 
alone, the current clinical standard for assessing 
response to treatment [9]. In this work, we have 
demonstrated that quantitative acoustic angiography 
is sensitive to changes in microvascular density 
induced by RT and its feasibility as a tool for 
predicting treatment response.  
We believe the clinical implications of our data 
are significant. In this tumor model, we have 
demonstrated that by quantifying the dynamic 
microvascular response to RT, tumor recurrence can 
be detected earlier than using tumor volume 
measurements alone. In clinical practice, irradiated 
tumors often do not significantly change in size until 
3-4 months after treatment and therefore 
post-treatment imaging is also not performed during 
this time [41]. For any cancer patient, early detection 
of cancer and early assessment of treatment response 
is critical for maximizing the chance of improving or 
maintaining quality of life. By decreasing the wait 
time between treatment and post-treatment 
evaluation, we may be able to increase the probability 
of successfully modifying an unsuccessful treatment 
strategy to one that is tailored to the patient. This is 
specifically important for RT, which by itself is often 
used with radical intent more than in a palliative 
setting.  
The results in this study using a rat FSA model 
demonstrate that changes in volumetric vascular 
density is a biomarker that presents differently in 
local control and local failure tumors in response to 
RT, and that vascular density regrowth associated 
with tumor recurrence in local failure tumors occurs 
significantly sooner than tumor volume regrowth. In 
the tumors that present local control, VVD and TV 





both decrease at similar rates until the tumor 
completely disappears.  
We observe three phases after RT in both the 
VVD and TV curves, as described by Kozin et al: 1) 
initial treatment response presented by a continued 
increase in TV and VVD, 2) tumor regression phase 
presented by decrease in TV and VVD, and in local 
failure tumors, 3) tumor recurrence phase [42]. In the 
initial treatment response phase, we observed an 
increase in VVD that occurred at a significantly 
greater rate than in untreated tumors, most likely due 
to short term inflammation and subsequent 
hypervascularization caused by the high-dose RT. 
This observation is supported by previous pre-clinical 
studies that observed hyperperfusion immediately 
after RT [26]. Days before TV recurrence (TVx) is 
measurable in the local failure tumors, the tumors 
begin to undergo a rapid increase in vascular density 
that can be visualized on imaging and quantitatively 
measured. While we do not have data supporting 
why vascular density increases earlier than tumor 
volume, prior evidence suggests that the tumor 
endothelium experiences stress-induced expression of 
vascular endothelial growth factor (VEGF) and 
αvβ3-integrins, therefore evading cell death and 
possibly promoting revascularization and tumor cell 
proliferation [43,44].  
In this study, we observed that the average 
tumor volume in the local failure tumors was larger 
than the local control tumors, in all dose groups, 
although the size difference was not significant due to 
variance. The increased likelihood of failure in RT 
treatment of larger tumors is consistent with radiation 
biology theory [45,46]. As expected, the tumor volume 
threshold corresponding with local control increased 
as a function of radiation dose (Table 3). We also 
observed that average initial vascular density was 
greater in local failure tumors compared to local 
control tumors; however, the differences were not 
significant and require further investigation (Figure 
7). Although a higher VVD at the time of treatment 
might be associated with an increase in tumor 
oxygenation and improved RT outcome, this 
hypothesis remains unanswered with conflicting 
reported results from previous studies [47]. Hypoxic 
tumors are known to be more radioresistant than 
normoxic tumors due to a number of reasons 
including the lower probability of reactive oxygen 
species being produced by ionizing radiation thus 
forming fewer DNA strand breaks, as well as the 
negative effect of hypoxia on the pathway for DNA 
damage repair resulting in a more radioresistant cell 
type [48]. While many previous studies have observed 
a positive correlation between vascular density and 
therapeutic response, others have reported that 
vascular density has no effect, or an inverse 
correlation with treatment response [47,49]. We 
speculate that in this particular tumor model, 
endothelial cells within the larger tumors, which 
inherently have a higher VVD, may undergo a smaller 
fraction of lethal radiation damage than smaller 
tumors and can eventually repair, possibly 
encouraging tumor regrowth. Due to the variability in 
tumor growth rates and unforeseen treatment 
scheduling complications, our initial size distribution 
was not comparable in all dose groups and is a 
confounding factor in explaining the effect of initial 
vascular density on treatment outcome.  
We observed earlier tumor recurrence with 
increasing dose; however, this requires further 
investigation. There are two possible explanations. 
First, as mentioned previously, the average initial 
(pre-treatment) TV was larger as dose increased, 
which may have resulted in a lower tumor cell kill 
fraction despite being treated with higher doses. 
Second, there is evidence that suggests that hypoxia 
induced by higher dose RT activates the unfolded 
protein response, protecting against hypoxia and 
resulting in the ability to more aggressively 
proliferate and metastasize [50]. However, further 
investigation is required to determine if FSA is 
affected by hypoxia-induced stress.  
We chose to use a simple, single high-dose 
fraction treatment to demonstrate feasibility of our 
imaging technique. Our dosage scheme was 
determined based on pilot study results 
(unpublished) of a longitudinal RT study performed 
at 0, 5, and 20 Gy in the same rat and tumor model. In 
the 20 Gy treatment group, ~50% resulted in local 
control. We chose doses between 15 and 25 Gy to 
investigate the TV and VVD differences between local 
controls and local failures while also determining any 
dose dependent responses. Conventional dose 
fractionation, or the division of the total radiation 
dose into multiple smaller doses over 7-8 weeks, is 
clinically used to reduce healthy tissue toxicity by 
allowing cellular repair in between successive 
treatments [51]. At this point, the effect of a dose 
fractionated scenario on tumor VVD is unclear and is 
an important, clinically relevant question that still 
needs to be answered. Our high-dose treatment 
conditions are more relevant to stereotactic body 
radiotherapy (SBRT) or stereotactic radiosurgery 
(SRS), and hypo-fractionated radiation therapy, which 
precisely deliver high dose radiation to the target 
tissue with just a single or few treatments [52]. 
Hypofractionation and SBRT/SRS, while relatively 
new and controversial in the field of radiotherapy, are 
promising techniques that may reduce toxicity while 
improving tumor control [52–54]. The results from 





this initial study motivate us to conduct further 
investigation under experimental conditions closer to 
more clinically relevant applications that incorporate 
conventional and hypo-fractionated RT.  
As mentioned previously, tumor hypoxia and 
necrosis play an important role in tumor response to 
radiation [50, 55]. The microvascular changes 
observed in this study are specific to the Fischer 344 
rat fibrosarcoma tumor model. Since this tumor strain 
has been shown to be highly oxygen dependent we 
made an assumption that areas of hypovascularity 
(hypoechoic regions) represented necrotic and 
perinecrotic regions [35]. The motivation for 
removing the hypoechoic regions was to prevent 
overestimation of the perfused tissue volume. 
However, histology was not performed to confirm the 
hypoechoic regions as necrotic/perinecrotic to 
validate our analysis. This can be performed in future 
studies using the TUNEL assay and hematoxylin and 
eosin staining [56].  
The diversity of human tumors is accompanied 
with a wide range of neovascularization patterns, 
including both avascular (hypoxic) and vascular 
development [7]. Further investigation using this 
technique in different types of human-derived tumor 
models is warranted since the microvascular response 
after exposure to radiation will likely vary among 
different tumor types. Regardless, we are encouraged 
from these results that quantitative microvascular 
measurements using acoustic angiography may 
significantly improve the current methods for 
treatment assessment.  
The current dual-frequency prototype 
transducer suffers from resolution and imaging depth 
limitations. The resolution of acoustic angiography is 
between 100-200 µm, which places a limitation on the 
smallest size tumor that can be accurately analyzed 
for VVD. Tumors less than 1 mm in diameter may 
inaccurately measure VVD as high as 20-50% due to 
the resolution limitation. Additionally, due to the 
fixed focus of the dual-frequency transducer, our 
depth of field was limited to approximately 1.0 cm 
axially with a maximum depth penetration of ~2 cm. 
Tumors near 2 cm in diameter were clipped at the top 
and bottom in order to maintain the focus of the 
transducer in the center of the tumor. Acoustic 
angiography experiences substantial one-way 
frequency dependent attenuation due to the high 
frequency receive bandwidth, which limits the 
imaging penetration depth to superficial organs. 
Decreasing the transducer receiving frequency will 
improve the imaging penetration depth and depth of 
field, however the signal-to-noise ratio would be 
compromised due to the reduced separation between 
tissue signal and higher harmonic contrast signal. 
Conversely, increasing the receiving frequency will 
improve resolution, but at the cost of decreasing 
contrast sensitivity, penetration depth, and depth of 
field. Despite these limitations, acoustic angiography 
has remarkably high resolution and contrast 
sensitivity relative to clinically available CEUS 
techniques. Further, development of a linear array 
dual-frequency transducer will enhance acoustic 
angiography with the increased depth of field and 
faster image acquisition required for clinical 
translation [57,58]. Nevertheless, due to the 
high-frequency receive bandwidth, acoustic 
angiography will always be limited to imaging targets 
within a few cm of the skin. Neck cancers, prostate, 
and breast cancers might be reasonable targets, 
however deeper cancers in organs such as the liver 
will not be accessible without an endoscopic imaging 
tool.  
It is also worth noting that new super-resolution 
imaging techniques may provide an alternative 
solution to imaging angiogenic vasculature with an 
order of magnitude better resolution once the 
technology matures. However, super resolution 
imaging still requires tens of minutes to acquire a 3D 
volume of data due to data acquisition and processing 
limitations [59]. 
In our study, we retrospectively categorized the 
treated tumors as local control or failure based on the 
final treatment outcome. The development of a 
predictive tool indicating treatment outcome based on 
repeated vascular density (or other vessel 
morphological features) and tumor volume 
measurements will be highly relevant to the clinical 
translation of this diagnostic technique. There has 
been a recent surge of interest in developing models 
for predicting a patient’s outcome to cancer 
therapy. The field of Radiomics, for example, has been 
established to use large sets of minable MR, CT and 
PET imaging data to extract quantitative features such 
as tumor sphericity, homogeneity, and volume. When 
combined with other patient medical data, it can be 
analyzed using advanced bioinformatics statistical 
techniques to determine correlations to tumor 
behavior and treatment response [60]. Similarly, with 
acoustic angiography image data, we can extract 
additional quantitative features that describe 
microvascular characteristics of certain tumors and 
their response to therapy. We plan to continue 
investigating changes in vessel morphology (using 
metrics to describe vessel tortuosity) and molecular 
expression in response to RT in future studies. 
Contrast-enhanced ultrasound imaging is a safe, 
inexpensive, and highly accessible imaging modality 
with many applications in all fields of oncology, and 
with on-going technical improvements, acoustic 





angiography is a promising and clinically translatable 
imaging technology. 
Conclusion 
While the biological basis for the variation of 
tumor response to radiation is still not entirely 
understood, there is a growing body of evidence that 
suggests that the tumor microvascular environment 
plays a significant role in radiation treatment efficacy. 
Our objective in this study was to assess tumor 
response to radiation by quantifying changes in 
vascularity that may be associated with treatment 
outcome. Our results demonstrated that vascular 
changes, specifically increases in vascular density, are 
a potential biomarker for assessing long-term tumor 
response to RT. We believe that providing a more 
timely and reliable method for assessing treatment 
response may enable clinical treatment decisions to be 
made earlier than the current standard of care, 
therefore improving cancer patient outcomes. 
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